Genetics Institute, Boehringer Mannheim GmbH deal

GENIZ restructured and expanded its license agreement with Boehringer Mannheim for erythropoietin (EPO), which is used to increase red blood cells and treat kidney disease-related anemia. The original agreement licensed Boehringer to sell EPO in Europe, South America, the Middle East, Africa, South Korea and China.

Under the new agreement, GENIZ granted Boehringer the right to sell EPO in several Asia-Pacific countries, as well as India, Australia and Taiwan. GENIZ will receive license fees and milestone payments for the new territories. Sales royalties from the new territories will be higher than the current rate, which is undisclosed. ...